Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

Despite the recent introduction of new effective systemic agents, the survival of patients with
hepatocellular carcinoma (HCC) at advanced stages remains dismal. This underscores the …

Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a
significant global health problem. The clinical applicability of traditional surgery and other …

Abstract RAS proteins (HRAS, KRAS, NRAS) participate in many physiological signal
transduction processes related to cell growth, division, and survival. The RAS proteins are …

Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of
the most common malignant tumours with a high rate of recurrence and mortality. Although …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide,
with nearly one million new cases and deaths every year. Owing to the complex …

Background and aims Circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) may
be used for diagnostic or prognostic purposes in patients with hepatocellular carcinoma …

Protein synthesis is important for maintaining cellular homeostasis under various stress
responses. In this study, we screened an anticancer drug library to select compounds with …

肝细胞癌是我国最常见的肝癌类型, 分子异质性显著, 极大地制约了临床疗效,
因此深入探索其异质性的分子分型, 对于制订个体化诊疗策略极为重要. 近年来多种高通量测序 …

Hepatocellular carcinoma (HCC) is one of the most common malignancies, and its treatment
is limited. With the understanding of key genes and signaling pathways in the occurrence …